STING1 and cancer: Accumulating evidence indicates that chemotherapy, radiotherapy, angiogenesis inhibitors, stimulator of interferon genes (STING) agonists, fecal microbiota transplantation (FMT), epigenetic modulators, and other immunomodulators can enhance the therapeutic effects of α-PD-1/PD-L1 immunotherapy by increasing cancer antigen release, enhancing antigen-presenting cell (APC) function, or augmenting effector activity 14-23.